Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at high risk for radiographic progression.
There was a strong, but not statistically significant, signal of reduced spinal structural damage with the combination of a selective COX-2 inhibitor and a TNF inhibitor in axial spondyloarthritis.